A Phase 3 interventional study of Pembrolizumab and Enzalutamide in Prostatic Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated at 259 sites in 28 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
The study stopped due to futility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing pembrolizumab in Prostatic Neoplasms — 4 open to participants now, 8 under way, none of them phase 3. pembrolizumab · Prostatic Neoplasms.
Among the 20 studies testing pembrolizumab in Prostatic Neoplasms, this one has the largest enrollment, is one of 4 that started in 2019, is one of 4 in phase 3, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 20 studies testing pembrolizumab in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2014; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,244 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 41 across the 20 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
22 studies in Prostatic Neoplasms by Merck & Co., Inc: 4 open now, 6 under way, 3 of them phase 3. Of 15 finished, 6 (40%) have results posted.
Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 5th largest by enrollment, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 10th registered.
Merck & Co., Inc’s Prostatic Neoplasms studies by the year they started, since 2003.
2 of the studies testing pembrolizumab in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766371University of California, San FranciscoPembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | 2027-05-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing pembrolizumab in Prostatic Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 22 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate. There are two primary study hypotheses.
Hypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Overall Survival (OS).
Hypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
Biological: Pembrolizumab · Drug: Enzalutamide
Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
Drug: Enzalutamide · Drug: Placebo
IV infusion
Also known as: KEYTRUDA®, MK-3475
Capsules/Tablets
Also known as: XTANDI®
IV infusion
Also known as: Normal saline or dextrose infusion
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause. The OS for all participants is presented.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review
rPFS was defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurred first. The rPFS per PCWG-modified RECIST for all participants is presented.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)
TFST was defined as time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first. The TFST for all participants is presented.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Prostate-specific Antigen (PSA) Response Rate
PSA response rate was defined as percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart. The analysis was performed on participants who had baseline PSA measurements.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Prostate-specific Antigen (PSA) Undetectable Rate
PSA undetectable rate was defined as percentage of participants in the analysis population with PSA \<0.2 ng/mL during study treatment. The analysis was performed on participants who had baseline PSA measurements.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
OR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on bone scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD per PCWG was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for ≥6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. If a participant had not progressed, the participant was censored at the date of last disease assessment.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Time to Prostate-specific Antigen (PSA) Progression
Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)
Time from randomization to pain progression. In this study, pain progression was assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Time to First Symptomatic Skeletal-related Event (SSRE)
Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Number of Participants Who Experience an Adverse Event (AE)
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who experienced an AE is presented.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who discontinued study treatment due to an AE is presented.
Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)
| Milestone | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Started | 621 | 623 |
| Treated | 615 | 620 |
| Completed | 0 | 0 |
| Not completed | 621 | 623 |
| Withdrew: Participants ongoing | 311 | 324 |
| Withdrew: Withdrawal by subject | 20 | 17 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 289 | 282 |
OS was defined as the time from randomization to death due to any cause. The OS for all participants is presented.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Overall Survival (OS) | 24.7 (22.0 to 26.8) | 27.3 (24.5 to 30.1) |
rPFS was defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurred first. The rPFS per PCWG-modified RECIST for all participants is presented.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review | 10.4 (8.4 to 12.5) | 9.0 (8.3 to 11.5) |
TFST was defined as time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first. The TFST for all participants is presented.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST) | 13.2 (11.7 to 15.7) | 12.6 (11.3 to 14.2) |
PSA response rate was defined as percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart. The analysis was performed on participants who had baseline PSA measurements.
| Percentage of participants | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Prostate-specific Antigen (PSA) Response Rate | 49.0 (44.9 to 53.1) | 45.1 (41.1 to 49.2) |
PSA undetectable rate was defined as percentage of participants in the analysis population with PSA \<0.2 ng/mL during study treatment. The analysis was performed on participants who had baseline PSA measurements.
| Percentage of participants | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Prostate-specific Antigen (PSA) Undetectable Rate | 13.1 (10.5 to 16.1) | 12.6 (10.0 to 15.5) |
OR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on bone scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).
| Percentage of participants | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review | 12.2 (9.8 to 15.1) | 9.3 (7.1 to 11.9) |
DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD per PCWG was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for ≥6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. If a participant had not progressed, the participant was censored at the date of last disease assessment.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review | 16.1 (1.4 to 35.3) | 21.5 (0.0 to 35.3) |
Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 6.4 (5.5 to 7.1) | 5.6 (4.9 to 6.9) |
Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review | 20.7 (18.0 to 30.1) | 26.3 (17.8 to NA) |
Time from randomization to pain progression. In this study, pain progression was assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score) | NA (23.3 to NA) | NA (NA to NA) |
Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone.
| Months | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Time to First Symptomatic Skeletal-related Event (SSRE) | NA (NA to NA) | NA (NA to NA) |
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who experienced an AE is presented.
| Participants | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Number of Participants Who Experience an Adverse Event (AE) | 594 | 596 |
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who discontinued study treatment due to an AE is presented.
| Participants | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide |
|---|---|---|
| Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) | 115 | 50 |
Collected over Up to 40 months (through database cut-off date of 12-Dec-2022). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab + Enzalutamide | 295/621 (47.5%) | 238/615 (38.7%) | 563/615 (91.5%) |
| Placebo + Enzalutamide | 291/623 (46.7%) | 165/620 (26.6%) | 551/620 (88.9%) |
| Pembrolizumab + Enzalutamide Second Course | 1/4 (25%) | 0/4 (0%) | 0/4 (0%) |
| Event | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Pembrolizumab + Enzalutamide Second Course |
|---|---|---|---|
| PneumoniaInfections and infestations | 16/615 | 10/620 | 0/4 |
| Urinary tract infectionInfections and infestations | 12/615 | 10/620 | 0/4 |
| Spinal cord compressionNervous system disorders | 9/615 | 11/620 | 0/4 |
| HaematuriaRenal and urinary disorders | 3/615 | 10/620 | 0/4 |
| PyrexiaGeneral disorders | 9/615 | 3/620 | 0/4 |
| UrosepsisInfections and infestations | 8/615 | 3/620 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 7/615 | 4/620 | 0/4 |
| COVID-19 pneumoniaInfections and infestations | 7/615 | 2/620 | 0/4 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/615 | 1/620 | 0/4 |
| COVID-19Infections and infestations | 6/615 | 3/620 | 0/4 |
| Event | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Pembrolizumab + Enzalutamide Second Course |
|---|---|---|---|
| FatigueGeneral disorders | 190/615 | 170/620 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 149/615 | 128/620 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 146/615 | 124/620 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 141/615 | 103/620 | 0/4 |
| RashSkin and subcutaneous tissue disorders | 139/615 | 43/620 | 0/4 |
| NauseaGastrointestinal disorders | 126/615 | 114/620 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 120/615 | 123/620 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 115/615 | 79/620 | 0/4 |
| ConstipationGastrointestinal disorders | 113/615 | 90/620 | 0/4 |
| AstheniaGeneral disorders | 109/615 | 97/620 | 0/4 |
| Age, Continuous(Years) | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Total |
|---|---|---|---|
| Mean | 70.6 ± 8.4 | 69.9 ± 9.1 | 70.3 ± 8.7 |
| Sex: Female, Male(Participants) | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 621 | 623 | 1244 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Total |
|---|---|---|---|
| Hispanic or Latino | 121 | 126 | 247 |
| Not Hispanic or Latino | 465 | 466 | 931 |
| Unknown or Not Reported | 35 | 31 | 66 |
| Race (NIH/OMB)(Participants) | Pembrolizumab + Enzalutamide | Placebo + Enzalutamide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 12 | 20 |
| Asian | 80 | 86 | 166 |
| Native Hawaiian or Other Pacific Islander | 3 | 3 | 6 |
| Black or African American | 12 | 10 | 22 |
| White | 505 | 494 | 999 |
| More than one race | 12 | 13 | 25 |
| Unknown or Not Reported | 1 | 5 | 6 |
Showing the first 100 of 259 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2019 to primary completion in Dec 2022, 40 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
The study stopped due to futility
The study stopped due to futility
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab